Wealth Enhancement Advisory Services LLC Has $63.27 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Wealth Enhancement Advisory Services LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,150 shares of the medical research company’s stock after selling 122 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $63,272,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. New England Research & Management Inc. grew its position in Thermo Fisher Scientific by 169.5% during the first quarter. New England Research & Management Inc. now owns 1,981 shares of the medical research company’s stock worth $986,000 after buying an additional 1,246 shares in the last quarter. CVA Family Office LLC boosted its holdings in shares of Thermo Fisher Scientific by 5.8% in the 1st quarter. CVA Family Office LLC now owns 1,530 shares of the medical research company’s stock valued at $761,000 after purchasing an additional 84 shares in the last quarter. Elevation Point Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 12.2% during the 1st quarter. Elevation Point Wealth Partners LLC now owns 1,366 shares of the medical research company’s stock valued at $680,000 after acquiring an additional 149 shares in the last quarter. West Branch Capital LLC boosted its holdings in shares of Thermo Fisher Scientific by 10.9% during the 1st quarter. West Branch Capital LLC now owns 3,008 shares of the medical research company’s stock valued at $1,497,000 after acquiring an additional 296 shares in the last quarter. Finally, Salem Investment Counselors Inc. boosted its holdings in shares of Thermo Fisher Scientific by 6.6% during the 1st quarter. Salem Investment Counselors Inc. now owns 18,822 shares of the medical research company’s stock valued at $9,368,000 after acquiring an additional 1,158 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Stifel Nicolaus cut their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Argus cut their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Evercore ISI lowered their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Finally, UBS Group lowered their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $605.30.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $392.54 on Friday. The stock has a 50-day moving average price of $413.43 and a 200-day moving average price of $488.79. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The firm has a market cap of $148.18 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 2.07 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the business posted $5.11 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.44%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.